The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1561
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
The full article is available to subscribers Subscriber Login   

The FDA has approved a new 2.5-mg formulation of the direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) for use in combination with low-dose aspirin to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban is the first direct oral anticoagulant to be approved for this indication. It was approved earlier for prevention and treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.1,2

SECONDARY PREVENTION — Most expert clinicians recommend aspirin 81-162 mg/day indefinitely for patients with atherosclerotic vascular disease (excluding those with aspirin hypersensitivity or a high risk of gastrointestinal bleeding).3 In ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
Article code: 1561b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian